Novartis on Tuesday revealed plans to invest $1bn to expand its Shanghai laboratories and make China the third pillar of its global research and development capabilities.

Daniel Vasella, chairman, said the Swiss drugs group would build a new campus in Shanghai to house its research activities, which would employ 1,000 scientists in five years’ time.